Cargando…
Practical approach to management of chronic lymphocytic leukemia
Revolutionary progress has recently changed the landscape of chronic lymphocytic leukemia (CLL). Powerful prognostic factors, especially p53 mutation and/or deletion and IGHV mutation status, have refined individual patient prognosis. Purine analogs and monoclonal antibodies paved the way from palli...
Autores principales: | Smolej, Lukáš, Šimkovič, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848353/ https://www.ncbi.nlm.nih.gov/pubmed/27186193 http://dx.doi.org/10.5114/aoms.2016.55424 |
Ejemplares similares
-
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
por: Roberts, AW, et al.
Publicado: (2016) -
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review
por: Quartermaine, Cooper, et al.
Publicado: (2023) -
Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
por: Smolej, Lukáš, et al.
Publicado: (2021) -
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia
por: Vodárek, Pavel, et al.
Publicado: (2022) -
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
por: Smolej, Lukáš
Publicado: (2014)